Core Viewpoint - The lawsuit against Xilong Science Co., Ltd. has progressed, with investors winning the final judgment and receiving compensation, while the company shows willingness to mediate [1][2]. Group 1: Legal Developments - Investors represented by Zhao Jingguo's legal team have achieved a final victory in their lawsuit against Xilong Science, with compensation awarded [1][2]. - The company received a notice of investigation from the China Securities Regulatory Commission (CSRC) on May 6, 2023, due to suspected violations of information disclosure laws [1][4]. - On July 7, 2023, Xilong Science was issued an administrative penalty decision by the CSRC, confirming that the company inflated revenue by fabricating trade activities involving ethylene glycol and methanol [1][4]. Group 2: Investor Compensation Conditions - Investors who purchased and held shares of Xilong Science between April 29, 2021, and April 28, 2023, are eligible to register for compensation, regardless of whether they sold their shares after April 29, 2023 [3][5]. - The specific compensation range will be determined by the court [5].

Core Viewpoint - *ST Weihai (002586.SZ) has been identified as a candidate for the contract of the "Smart Agriculture Project in Luoping County, Qujing City, Yunnan Province" with a bid amount of 652.275 million yuan [1] Group 1 - The project is a joint venture led by Zhejiang Weihai Construction Group Co., Ltd. and China Southwest Architectural Design and Research Institute [1] - The bid amount for the project is 65,227.50 million yuan, subject to final contract negotiations [1] - The public announcement period for the bid results is from December 8, 2025 [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 湯臣集團有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00258 | 說明 | 不適用 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000, ...

Group 1 - The core point of the article is that ST Weiming (002581.SZ) announced a plan for significant share reduction by its shareholders Gao Baolin and Wang Mingxian, which may impact the stock's performance [1] Group 2 - The shareholders plan to reduce their holdings by up to 19.79 million shares, which represents 3% of the company's total share capital [1] - The reduction will take place within three months after a 15 trading day period following the announcement, utilizing centralized bidding and block trading methods [1]

Core Viewpoint - The company *ST Weihai has been awarded a contract for the construction of the Huaihe River to Sea Waterway Phase II project, marking a significant development in its project portfolio [1] Group 1: Project Announcement - The company announced on October 28, 2025, that it has been selected as the winning bidder for the "Huaihe River to Sea Waterway Phase II Project (within Huai'an City)" [1] - The company has signed a construction contract with relevant parties for the project [1] Group 2: Contract Details - The signed contract value amounts to 312,956,420.04 yuan [1]

Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, to conduct a Phase III clinical trial for its innovative drug, recombinant human nerve growth factor SMR001 eye drops, aimed at treating moderate to severe dry eye syndrome [1] Summary by Categories Company Developments - The ethical approval for the Phase III clinical trial signifies that the project has met the necessary ethical compliance requirements to proceed [1] - The initiation of this clinical trial is not expected to have a significant impact on the company's operating performance in the short term [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 湯臣集團有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00258 | 說明 不適用 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000, ...

Core Points - ST Unimed (002581.SZ) released its Q3 2025 financial report on October 29, 2025 [1] - As of October 28, 2025, six institutional investors disclosed holdings in ST Unimed A-shares, totaling 139 million shares, which represents 21.07% of the total share capital [1] - The institutional investors include Xiamen Hengxing Group Co., Ltd., Shenzhen Jialian Private Securities Investment Fund Management Co., Ltd. - Jialian No. 1 Securities Investment Fund, Shenzhen Yilian Technology Co., Ltd., Shenzhen Juyunlai Investment Partnership (Limited Partnership), Beijing Peking University Unimed Bioengineering Group Co., Ltd., and Shenwan Hongyuan Securities Co., Ltd. [1] - The total institutional holding percentage decreased by 1.31 percentage points compared to the previous quarter [1] - In terms of public funds, 13 public funds were not disclosed in this period compared to the previous quarter, including Southern CSI 1000 ETF, Huaxia CSI 1000 ETF, GF CSI 1000 ETF, Fortune CSI 1000 Index Enhanced A, and China Merchants CSI 1000 Index Enhanced A [1]

Core Viewpoint - Company *ST Weihai (002586.SZ) has been identified as the preferred bidder for the "Huaihe River to Sea Waterway Phase II Project (within Huai'an City) River Engineering Construction Package 14" with a bid price of 313 million yuan [1] Summary by Category - **Project Details** - The project involves river engineering construction as part of the Huaihe River to Sea Waterway Phase II [1] - The public announcement period for the bid is from October 11, 2025, to October 14, 2025 [1]

Core Points - Company *ST Weihai has been identified as the preferred bidder for the "Huaihe River Estuary Phase II Project (within Huai'an City) River Engineering Construction Lot 14" [1] - The bid amount for the project is 312,956,420.04 yuan, with the final contract amount to be determined upon signing [1] - The public announcement period for this bid is from October 11, 2025, to October 14, 2025 [1]